JP4761623B2 - 新規連鎖球菌抗原 - Google Patents

新規連鎖球菌抗原 Download PDF

Info

Publication number
JP4761623B2
JP4761623B2 JP2000591190A JP2000591190A JP4761623B2 JP 4761623 B2 JP4761623 B2 JP 4761623B2 JP 2000591190 A JP2000591190 A JP 2000591190A JP 2000591190 A JP2000591190 A JP 2000591190A JP 4761623 B2 JP4761623 B2 JP 4761623B2
Authority
JP
Japan
Prior art keywords
polypeptide
seq
bvh
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000591190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002533123A (ja
JP2002533123A5 (enExample
Inventor
ジョゼ・アメル
ベルナール・エール・ブロドゥール
イザベル・ピノー
デニ・マルタン
クレマン・リュー
ナタリー・シャルラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Id Biomedical Corp
Original Assignee
Id Biomedical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4761623(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Id Biomedical Corp filed Critical Id Biomedical Corp
Publication of JP2002533123A publication Critical patent/JP2002533123A/ja
Publication of JP2002533123A5 publication Critical patent/JP2002533123A5/ja
Application granted granted Critical
Publication of JP4761623B2 publication Critical patent/JP4761623B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2000591190A 1998-12-23 1999-12-20 新規連鎖球菌抗原 Expired - Fee Related JP4761623B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11380098P 1998-12-23 1998-12-23
US60/113,800 1998-12-23
PCT/CA1999/001218 WO2000039299A2 (en) 1998-12-23 1999-12-20 Streptococcus antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010026521A Division JP5039802B2 (ja) 1998-12-23 2010-02-09 新規連鎖球菌抗原

Publications (3)

Publication Number Publication Date
JP2002533123A JP2002533123A (ja) 2002-10-08
JP2002533123A5 JP2002533123A5 (enExample) 2007-01-25
JP4761623B2 true JP4761623B2 (ja) 2011-08-31

Family

ID=22351610

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000591190A Expired - Fee Related JP4761623B2 (ja) 1998-12-23 1999-12-20 新規連鎖球菌抗原
JP2010026521A Expired - Fee Related JP5039802B2 (ja) 1998-12-23 2010-02-09 新規連鎖球菌抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010026521A Expired - Fee Related JP5039802B2 (ja) 1998-12-23 2010-02-09 新規連鎖球菌抗原

Country Status (29)

Country Link
EP (2) EP1141306B1 (enExample)
JP (2) JP4761623B2 (enExample)
KR (4) KR101170203B1 (enExample)
CN (3) CN1191362C (enExample)
AP (1) AP2001002199A0 (enExample)
AR (1) AR029322A1 (enExample)
AT (1) ATE394489T1 (enExample)
AU (1) AU1764900A (enExample)
BR (1) BR9916477A (enExample)
CA (1) CA2356836C (enExample)
CL (1) CL2009002037A1 (enExample)
CY (3) CY1108223T1 (enExample)
CZ (2) CZ302790B6 (enExample)
DE (1) DE69938670D1 (enExample)
DK (3) DK1141306T3 (enExample)
EA (1) EA007409B1 (enExample)
ES (3) ES2480417T3 (enExample)
HU (1) HU229664B1 (enExample)
IL (3) IL143905A0 (enExample)
MX (1) MXPA01006427A (enExample)
NO (1) NO330800B1 (enExample)
NZ (1) NZ512574A (enExample)
OA (1) OA11736A (enExample)
PL (3) PL206576B1 (enExample)
PT (3) PT2261358E (enExample)
TR (2) TR200102497T2 (enExample)
UY (1) UY25877A1 (enExample)
WO (1) WO2000039299A2 (enExample)
ZA (1) ZA200105114B (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27482A (id) 1998-02-20 2001-04-12 Iaf Biochem Int Antigen streptococcus kelompok b
US20030134407A1 (en) 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP1801218A3 (en) * 1998-07-27 2007-10-10 Sanofi Pasteur Limited Nucleic acids and proteins from streptococcus pneumoniae
DE69940439D1 (de) * 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
NZ512574A (en) * 1998-12-23 2004-03-26 Iaf Biochem Int Novel streptococcus antigens useful as vaccines
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US6833134B2 (en) 2000-06-12 2004-12-21 University Of Saskacthewan Immunization of dairy cattle with GapC protein against Streptococcus infection
DE60136356D1 (de) 2000-06-12 2008-12-11 Univ Saskatchewan Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik
US6866855B2 (en) 2000-06-12 2005-03-15 University Of Saskatchewan Immunization of dairy cattle with GapC protein against Streptococcus infection
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
EP2281891A3 (en) 2000-06-20 2011-08-17 ID Biomedical Corporation Streptococcus antigens
AU2002242549A1 (en) * 2001-03-30 2002-10-15 Shire Biochem Inc. Streptococcus pyogenes antigens and corresponding dna fragments
DE60234772D1 (de) 2001-07-06 2010-01-28 Id Biomedical Corp Gruppe-b streptococcus antigene und entsprechende dna-fragmente
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
AU2002351623A1 (en) * 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
CA2517518A1 (en) 2003-03-04 2004-09-16 Intercell Ag Streptococcus pyogenes antigens
EP2311987A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
ES2707499T3 (es) 2005-12-22 2019-04-03 Glaxosmithkline Biologicals Sa Vacuna de conjugado de polisacárido neumocócico
EA201391788A1 (ru) 2007-06-26 2014-08-29 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
CA2694466A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
HUE026586T2 (hu) * 2008-04-16 2016-06-28 Glaxosmithkline Biologicals Sa Vakcina
CN102223876A (zh) 2008-09-26 2011-10-19 纳米生物公司 纳米乳剂治疗性组合物及其使用方法
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
PT2473605T (pt) 2009-09-03 2018-05-28 Pfizer Vaccines Llc Vacina pcsk9
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
CA2834834A1 (en) 2011-05-17 2012-11-22 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
US10161940B2 (en) * 2012-01-05 2018-12-25 Deutsches Krebsforschungszentrum Means and methods for treating or diagnosing IDH1 R132H mutant-positive cancers
WO2014089706A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PE20161095A1 (es) 2014-01-21 2016-10-26 Pfizer Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
DK3096783T3 (da) 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
HRP20211288T1 (hr) 2014-01-21 2021-11-26 Pfizer Inc. Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
WO2015121783A1 (en) 2014-02-14 2015-08-20 Pfizer Inc. Immunogenic glycoprotein conjugates
HRP20230416T1 (hr) 2015-01-15 2023-07-07 Pfizer Inc. Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
KR20250058066A (ko) 2015-07-21 2025-04-29 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020121159A1 (en) 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
CA3136278A1 (en) 2019-04-10 2020-10-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
KR20220042378A (ko) 2019-07-31 2022-04-05 사노피 파스퇴르 인코포레이티드 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법
KR20220092572A (ko) 2019-11-01 2022-07-01 화이자 인코포레이티드 에스케리키아 콜라이 조성물 및 그 방법
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
EP4107170A2 (en) 2020-02-23 2022-12-28 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023005221A (es) 2020-11-04 2023-05-16 Pfizer Composiciones inmunogenicas para uso en vacunas neumococicas.
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
EP4333879A1 (en) 2021-05-03 2024-03-13 Pfizer Inc. Vaccination against bacterial and betacoronavirus infections
WO2022234416A1 (en) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
EP4346893A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112023023671A2 (pt) 2021-05-28 2024-02-06 Pfizer Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos
CN118510548A (zh) 2022-01-13 2024-08-16 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其用途
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
JP2025516536A (ja) 2022-05-11 2025-05-30 ファイザー・インク 保存剤を用いたワクチン製剤を作製するためのプロセス
WO2024084397A1 (en) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination against pneumoccocal and covid-19 infections
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
AU2023385908A1 (en) 2022-11-22 2025-05-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
EP4661911A1 (en) 2023-02-10 2025-12-17 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024201324A2 (en) 2023-03-30 2024-10-03 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh) 2023-04-14 2025-12-02 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2025057078A1 (en) 2023-09-14 2025-03-20 Pfizer Inc. Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
WO2025133971A1 (en) 2023-12-23 2025-06-26 Pfizer Inc. Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en) 2024-03-11 2025-09-18 Pfizer Inc. Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en) 2024-04-19 2025-10-23 Pfizer Inc. Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025219908A2 (en) 2024-04-19 2025-10-23 Pfizer Inc. Media and fermentation methods for polysaccharide production in bacterial cell culture

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
WO1994021685A1 (en) * 1993-03-19 1994-09-29 Gunnar Lindahl Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
JPH11507214A (ja) * 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
US5882896A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5928895A (en) * 1996-09-24 1999-07-27 Smithkline Beecham Corporation IgA Fc binding protein
CN1291233A (zh) * 1997-09-24 2001-04-11 美国明尼苏达州大学 来自肺炎链球菌之人类补体c3降解蛋白酶
WO1999053940A1 (en) * 1998-04-23 1999-10-28 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
WO2000006737A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
JP2002526082A (ja) * 1998-09-24 2002-08-20 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ストレプトコッカス・ニューモニア由来のヒト補体ｃ３分解ポリペプチド
DE69940439D1 (de) * 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
NZ512574A (en) * 1998-12-23 2004-03-26 Iaf Biochem Int Novel streptococcus antigens useful as vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO1998018931A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences

Also Published As

Publication number Publication date
EA007409B1 (ru) 2006-10-27
ES2480417T3 (es) 2014-07-28
NO20013045L (no) 2001-08-20
HU229664B1 (en) 2014-04-28
ES2400280T3 (es) 2013-04-08
AP2001002199A0 (en) 2001-09-30
DK2261358T3 (da) 2014-07-28
JP5039802B2 (ja) 2012-10-03
JP2002533123A (ja) 2002-10-08
NZ512574A (en) 2004-03-26
KR20010104693A (ko) 2001-11-26
TR200102497T2 (tr) 2002-01-21
CY1115340T1 (el) 2017-01-04
CY1114722T1 (el) 2016-10-05
EP1141306B1 (en) 2008-05-07
KR100891398B1 (ko) 2009-04-02
CZ302790B6 (cs) 2011-11-09
CA2356836A1 (en) 2000-07-06
EA200100565A1 (ru) 2002-04-25
ZA200105114B (en) 2002-11-21
EP2261358B1 (en) 2014-05-14
PL204073B1 (pl) 2009-12-31
KR100802198B1 (ko) 2008-02-11
HK1118575A1 (en) 2009-02-13
IL194230A0 (en) 2011-08-01
HUP0104774A3 (en) 2007-10-29
DK1141306T3 (da) 2008-08-18
PT2261358E (pt) 2014-07-30
CN1332803A (zh) 2002-01-23
EP1141306A2 (en) 2001-10-10
OA11736A (en) 2005-06-12
PL349777A1 (en) 2002-09-09
ES2306528T3 (es) 2008-11-01
CN100398653C (zh) 2008-07-02
MXPA01006427A (es) 2002-06-04
UY25877A1 (es) 2000-08-21
KR20100063814A (ko) 2010-06-11
CA2356836C (en) 2011-09-13
PT1141306E (pt) 2008-07-30
TR200200633T2 (tr) 2002-06-21
EP2261358A2 (en) 2010-12-15
IL143905A0 (en) 2002-04-21
KR101078919B1 (ko) 2011-11-01
JP2010142246A (ja) 2010-07-01
AR029322A1 (es) 2003-06-25
ATE394489T1 (de) 2008-05-15
CZ20012161A3 (cs) 2001-10-17
PT1950302E (pt) 2013-01-16
CN1191362C (zh) 2005-03-02
EP2261358A3 (en) 2011-02-23
IL143905A (en) 2011-05-31
CN101134775A (zh) 2008-03-05
KR20060134227A (ko) 2006-12-27
CY1108223T1 (el) 2014-02-12
CL2009002037A1 (es) 2010-06-25
CZ303675B6 (cs) 2013-02-27
KR101170203B1 (ko) 2012-07-31
PL205041B1 (pl) 2010-03-31
DK1950302T3 (da) 2013-01-14
DE69938670D1 (de) 2008-06-19
NO330800B1 (no) 2011-07-18
IL194230A (en) 2013-12-31
AU1764900A (en) 2000-07-31
PL206576B1 (pl) 2010-08-31
KR20080036666A (ko) 2008-04-28
CN1654657A (zh) 2005-08-17
WO2000039299A2 (en) 2000-07-06
WO2000039299A3 (en) 2000-11-02
NO20013045D0 (no) 2001-06-19
BR9916477A (pt) 2004-06-22
HUP0104774A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
JP4761623B2 (ja) 新規連鎖球菌抗原
US8211437B2 (en) Streptococcus antigens
US7262024B2 (en) Streptococcus antigens
JP5051959B2 (ja) ストレプトコッカス抗原
US20030228323A1 (en) Novel group B streptococcus antigens
JP4718099B2 (ja) ストレプトコッカス・パイオジェンス抗原
US7074415B2 (en) Streptococcus antigens
EP1950302B1 (en) Streptococcus antigens
AU2005209689B2 (en) Novel streptococcus antigens
HK1118575B (en) Streptococcus antigens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061130

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100830

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110607

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140617

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140617

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140617

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees